-
Novo Nordisk plans new study for CagriSema, targets 2026 submission
06 Feb 2025 19:48 GMT
Novo Nordisk is planning a new Phase … either obese or overweight.
Novo Nordisk’s CEO Lars Fruergaard Jorgensen said the … lot riding on CagriSema as Novo Nordisk aims to quell the erosion … open following the Q4 results. Novo Nordisk has a market cap of …
-
Novo Nordisk defends next-gen obesity drug CagriSema, details new trial
06 Feb 2025 12:33 GMT
LONDON/COPENHAGEN - Novo Nordisk defended its next-generation obesity … drug Wegovy, Martin Holst Lange, Novo Nordisk's executive vice president … .
Lange's comments echoed CEO Lars Fruergaard Jorgensen's …
-
Novo Nordisk Opposes 'Government Price Setting' As Elon Musk's DOGE Gains Access To CMS Amid Bernie Sanders' Criticism
06 Feb 2025 09:12 GMT
… Global Business Development at Novo Nordisk.
The pricing debate has … , including Tesla Inc. CEO Elon Musk and Sen. … access.
Despite these challenges, Novo Nordisk remains focused on market … said.
Looking ahead, Novo Nordisk projects sales growth between 16% …
-
Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
06 Feb 2025 03:00 GMT
… a rocky few months for Novo Nordisk.
Prescription data from IQVIA suggests … an interview with CNBC, Novo Chief Executive Officer Lars Fruergaard Jorgensen brushed …
-
Oral Metabolic Drug Acquired by Novo Nordisk Continues to Show Concerning Neuro Side Effects
06 Feb 2025 00:48 GMT
… market in 2008.
Zelis CEO Amanda Eisel shares her … INV-202, came from Novo Nordisk’s 2023 acquisition of … weight loss.
Last September, Novo Nordisk reported Phase 2 obesity … irritability, and sleep disturbances. Novo Nordisk said these effects were more …
-
Novo Nordisk Stock Jumps On Q4 Beat: Retail Brushes Off Slower Growth Outlook To Chase Obesity Drug Boom
05 Feb 2025 21:38 GMT
… IST
NYSE-listed shares of Novo Nordisk surged 4% on Wednesday morning … growth rate in 2024, though CEO Lars Fruergaard Jørgensen emphasized …
-
Ozempic-maker Novo Nordisk’s sales double but rivals dent forecasts
05 Feb 2025 19:35 GMT
… -loss drugs market has caused Novo Nordisk, the pharmaceutical company, to forecast … decade.
Lars Fruergaard Jorgensen, the chief executive of Novo Nordisk, said: “We see an … during January 2025.”
Shares in Novo Nordisk rose DKr23, or 3.9 …
-
Novo Nordisk (NVO) Q4 2024 Earnings Call Transcript
05 Feb 2025 17:27 GMT
… relations at Novo Nordisk. With me today, I have CEO of Novo Nordisk, Lars Fruergaard … Fruergaard Jorgensen -- President and Chief Executive Officer Thank you, Karsten. … Fruergaard Jorgensen -- President and Chief Executive Officer
Camilla Sylvest -- …
-
Novo Nordisk missed its diversity targets last year, and its CEO paid a financial price
05 Feb 2025 17:40 GMT
-
Novo Nordisk CEO expects 'the same absolute growth' for 2025
05 Feb 2025 15:35 GMT
Novo Nordisk (NVO) shares gain after the … despite warnings of slower growth. Novo Nordisk CEO Lars Fruergaard Jørgensen sits … the coming year," the CEO adds, explaining, "We are … ørgensen highlights the prominence of Novo Nordisk's GLP-1 weight …
About
© 1995-2025